Everist Genomics Announces Worldwide Availability of OncoDefenderâ„¢-CRC
ANN ARBOR, Mich., March 28, 2011 /PRNewswire/ -- Everist Genomics today announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor. The OncoDefender-CRC test examines expression levels of a panel of genes extracted from formalin-fixed paraffin-embedded cancer tissue taken at the time of surgery, and uses a proprietary computer-generated decision rule to identify patients who are at risk of recurrence. Patients identified by OncoDefender-CRC at high-risk of cancer recurrence may benefit from adjuvant therapy or other more aggressive treatment options, as reported at the 2011 American Society of Clinical Oncology (ASCO) meeting. (1)
"We are pleased to deliver a new molecular prognostic test capable of assessing recurrence risk in early stage colorectal cancer patients, including the neglected stage I subset, where the lack of positive predictive prognostics presents a significant unmet need," said Prasad Sunkara, Ph.D., Chief Executive Officer of Everist Genomics. OncoDefender-CRC was developed through extensive clinical research and assay validation studies involving over 500 patients from around the world. "OncoDefender-CRC will help physicians make patient management decisions that promptly and reliably direct the most effective treatment to those individual Stage I/II colon cancer and Stage I rectal cancer patients at high risk for tumor recurrence, while minimizing the exposure of low-risk patients to unnecessary, costly, and potentially toxic chemotherapy and/or radiotherapy."
Traditional standards for assessing a patient's risk of cancer recurrence have depended solely on the cancer's a